197 related articles for article (PubMed ID: 33277507)
1. Long-term safety of tiotropium/olodaterol in older patients with moderate-to-very-severe COPD in the TONADO® studies.
Ferguson GT; Maltais F; Karpel J; Bothner U; Kloer I; Trampisch M; Buhl R
NPJ Prim Care Respir Med; 2020 Dec; 30(1):53. PubMed ID: 33277507
[TBL] [Abstract][Full Text] [Related]
2. Long-term safety of tiotropium/olodaterol Respimat
LaForce C; Derom E; Bothner U; Kloer IM; Trampisch M; Buhl R
Int J Chron Obstruct Pulmon Dis; 2018; 13():1819-1831. PubMed ID: 29910611
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO
Ferguson GT; Karpel JP; Clerisme-Beaty E; Grönke L; Voß F; Buhl R
Int J Chron Obstruct Pulmon Dis; 2016; 11():2701-2710. PubMed ID: 27843306
[TBL] [Abstract][Full Text] [Related]
4. Lung function and long-term safety of tiotropium/olodaterol in East Asian patients with chronic obstructive pulmonary disease.
Bai C; Ichinose M; Lee SH; Lee KH; Jöns O; Bothner U; Zhao Y; Buhl R
Int J Chron Obstruct Pulmon Dis; 2017; 12():3329-3339. PubMed ID: 29200840
[TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety of combined tiotropium and olodaterol via the Respimat(®) inhaler in patients with COPD: results from the Japanese sub-population of the Tonado(®) studies.
Ichinose M; Taniguchi H; Takizawa A; Grönke L; Loaiza L; Voß F; Zhao Y; Fukuchi Y
Int J Chron Obstruct Pulmon Dis; 2016; 11():2017-27. PubMed ID: 27621608
[TBL] [Abstract][Full Text] [Related]
6. Long-term general and cardiovascular safety of tiotropium/olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease.
Buhl R; Magder S; Bothner U; Tetzlaff K; Voß F; Loaiza L; Vogelmeier CF; McGarvey L
Respir Med; 2017 Jan; 122():58-66. PubMed ID: 27993292
[TBL] [Abstract][Full Text] [Related]
7. Benefits of Tiotropium/Olodaterol Compared with Tiotropium in Patients with COPD Receiving only LAMA at Baseline: Pooled Analysis of the TONADO
Buhl R; Singh D; de la Hoz A; Xue W; Ferguson GT
Adv Ther; 2020 Aug; 37(8):3485-3499. PubMed ID: 32462607
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Tiotropium + Olodaterol in Patients with Chronic Obstructive Pulmonary Disease by Initial Disease Severity and Treatment Intensity: A Post Hoc Analysis.
Ferguson GT; Fležar M; Korn S; Korducki L; Grönke L; Abrahams R; Buhl R
Adv Ther; 2015 Jun; 32(6):523-36. PubMed ID: 26112656
[TBL] [Abstract][Full Text] [Related]
9. No Influence on Cardiac Arrhythmia or Heart Rate from Long-Term Treatment with Tiotropium/Olodaterol versus Monocomponents by Holter ECG Analysis in Patients with Moderate-to-Very-Severe COPD.
Andreas S; Bothner U; de la Hoz A; Kloer I; Trampisch M; Alter P
Int J Chron Obstruct Pulmon Dis; 2020; 15():1945-1953. PubMed ID: 32848380
[TBL] [Abstract][Full Text] [Related]
10. Absence of Adverse Effects of Tiotropium/Olodaterol Compared with the Monocomponents on Long-Term Heart Rate and Blood Pressure in Patients with Moderate-to-Very-Severe COPD.
Andreas S; McGarvey L; Bothner U; Trampisch M; de la Hoz A; Fležar M; Buhl R; Alter P
Int J Chron Obstruct Pulmon Dis; 2020; 15():1935-1944. PubMed ID: 32848379
[TBL] [Abstract][Full Text] [Related]
11. Effect of tiotropium and olodaterol on symptoms and patient-reported outcomes in patients with COPD: results from four randomised, double-blind studies.
Ferguson GT; Karpel J; Bennett N; Clerisme-Beaty E; Grönke L; Voß F; Buhl R
NPJ Prim Care Respir Med; 2017 Feb; 27(1):7. PubMed ID: 28154373
[TBL] [Abstract][Full Text] [Related]
12. Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat® fixed-dose combination for chronic obstructive pulmonary disease patients in Italy.
Selya-Hammer C; Gonzalez-Rojas Guix N; Baldwin M; Ternouth A; Miravitlles M; Rutten-van Mölken M; Goosens LM; Buyukkaramikli N; Acciai V
Ther Adv Respir Dis; 2016 Oct; 10(5):391-401. PubMed ID: 27405723
[TBL] [Abstract][Full Text] [Related]
13. Tiotropium/Olodaterol Delays Clinically Important Deterioration Compared with Tiotropium Monotherapy in Patients with Early COPD: a Post Hoc Analysis of the TONADO
Rabe KF; Chalmers JD; Miravitlles M; Kocks JWH; Tsiligianni I; de la Hoz A; Xue W; Singh D; Ferguson GT; Wedzicha J
Adv Ther; 2021 Jan; 38(1):579-593. PubMed ID: 33175291
[TBL] [Abstract][Full Text] [Related]
14. Effects of baseline symptom burden on treatment response in COPD.
Martinez FJ; Abrahams RA; Ferguson GT; Bjermer L; Grönke L; Voß F; Singh D
Int J Chron Obstruct Pulmon Dis; 2019; 14():181-194. PubMed ID: 30655665
[TBL] [Abstract][Full Text] [Related]
15. [The efficacy and safety of tiotropium/olodaterol fixed-dose combination in Chinese patients with chronic obstructive pulmonary disease: a pooled subgroup analysis of TONADO 1+2].
Bai CX; Tang Y; Xin JB; Li YL; Li ZK; Kang J; Huang JA; Xiao W; Wen ZG; Fu XH; He B; Liu CT; Chen P
Zhonghua Jie He He Hu Xi Za Zhi; 2019 Nov; 42(11):838-844. PubMed ID: 31694094
[No Abstract] [Full Text] [Related]
16. Tiotropium/Olodaterol Decreases Exacerbation Rates Compared with Tiotropium in a Range of Patients with COPD: Pooled Analysis of the TONADO
Wedzicha JA; Buhl R; Singh D; Vogelmeier CF; de la Hoz A; Xue W; Anzueto A; Calverley PMA
Adv Ther; 2020 Oct; 37(10):4266-4279. PubMed ID: 32776202
[TBL] [Abstract][Full Text] [Related]
17. Safety of tiotropium/olodaterol in chronic obstructive pulmonary disease: pooled analysis of three large, 52-week, randomized clinical trials.
Ferguson GT; Buhl R; Bothner U; Hoz A; Voß F; Anzueto A; Calverley PMA
Respir Med; 2018 Oct; 143():67-73. PubMed ID: 30261995
[TBL] [Abstract][Full Text] [Related]
18. Impact of tiotropium + olodaterol on physical functioning in COPD: results of an open-label observational study.
Sauer R; Hänsel M; Buhl R; Rubin RA; Frey M; Glaab T
Int J Chron Obstruct Pulmon Dis; 2016; 11():891-8. PubMed ID: 27217742
[TBL] [Abstract][Full Text] [Related]
19. The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease.
Beeh KM; Westerman J; Kirsten AM; Hébert J; Grönke L; Hamilton A; Tetzlaff K; Derom E
Pulm Pharmacol Ther; 2015 Jun; 32():53-9. PubMed ID: 25956072
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of tiotropium/olodaterol on lung volume, exercise capacity, and physical activity.
Ichinose M; Minakata Y; Motegi T; Ueki J; Gon Y; Seki T; Anzai T; Nakamura S; Hirata K
Int J Chron Obstruct Pulmon Dis; 2018; 13():1407-1419. PubMed ID: 29750027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]